[{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$12,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Announces Termination of Co-promotion Agreement with Viatris for Lipitor\u00ae Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Indication BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEXLETOL\u00ae (Bempedoic Acid) Tablet, Ezetimibe and Atorvastatin Combination Lowered Bad Cholesterol by 60.5% vs. Placebo in Phase 2 Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Publishes New Data Highlighting Apabetalone\u2019s Benefit in Non-alcoholic Fatty Liver Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma, Inc Announces that Atorvaliq, the First and Only FDA-approved Liquid Suspension of Atorvastatin is Now Available","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"HealthBioAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HealthBioAI Announces the Acceptance by the Food and Drug Administration (FDA) to Proceed with a Randomized Clinical Trial for the Treatment of Long COVID\/Post Acute Sequelae of COVID (PASC) with Selzentry\u00ae (maraviroc) in Combination with Lipitor (atorvas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Atorvastatin
Selzentry (maraviroc) is a CCR5 co-receptor antagonist, in combination with Lipitor (atorvastatin) is being evaluated for the treatment of Long COVID/Post Acute Sequelae of COVID.
Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.
Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.
Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascular disease risk.
The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).
Astellas and Viatris have agreed to end the co-promotion of a hypercholesterolemia and familial hypercholesterolemia treatment “Lipitor® Tablets 5mg, 10mg” manufactured and sold by Astellas.
The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.
The U.S. Patent covers pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.
Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Upjohn’s Caduet.
The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
